ASH 2021 | Phase II trial of enasidenib in IDH2-mutant MDS
Enasidenib is a selective IDH2 inhibitor, approved by the FDA for the treatment of patients with relapsed/refractory (R/R) IDH2-mutated acute myeloid leukemia (AML). To investigate its efficacy in patients with IDH2-mutant myelodysplastic syndromes (MDS), a Phase II study has been set up and recruitment has begun (NCT03744390). The study is enrolling three patient cohorts: higher-risk MDS with hypomethylating agent (HMA) failure, untreated higher-risk MDS without life threatening cytopenias, and lower-risk MDS with erythropoiesis stimulating agent (ESA) failure. Uwe Platzbecker, MD, University Clinic Leipzig, Leipzig, Germany, comments on the progress made to date, with 45 patients enrolled and early data reflecting what is seen in AML. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
